ct

Sign in

FDA DODAC Approves Eyelash Drug

Contact Author Katie Schaefer
Close
Fill out my online form.

Allergan Inc. has announced that the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) voted unanimously (9-0) to recommend that the FDA approve Latisse (bimatoprost solution 0.03%) as a treatment for hypotrichosis or reduced amount of hair of the eyelashes.

The drug is a spinoff of the glaucoma drug Lumigan. In treating glaucoma, consumers noticed longer, darker and thicker eyelashes as a side effect of their treatment.

If approved, Latisse would be the first and only FDA-approved pharmaceutical to enhance eyelash prominence. If approved, Latisse will offer consumers an FDA-approved product which has been extensively studied in well-controlled clinical trials, is manufactured to pharmaceutical standards, is appropriately labeled for use and is regulated as a prescription product. 

In addition to its unanimous recommendation for approval of Latisse, the Committee also voted 5-3 (1 abstained vote) in favor of Phase 4 (post-market studies) to assess use in certain patient populations, including patients of younger age and post-chemotherapy patients with loss of eyelashes. The Committee's recommendation, although not binding, will be considered by the FDA as it contemplates approval for Latisse as a treatment for eyelash growth. If approved by the FDA, Allergan anticipates launching Latisse in 2009.

 

Close

Next image >